BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection

Authors: Mills, Richard J., Humphrey, Sean J., Fortuna, Patrick R.J., Lor, Mary, Foster, Simon R., Quaife-Ryan, Gregory A., Johnston, Rebecca L., Dumenil, Troy, Bishop, Cameron, Rudraraju, Rajeev, Rawle, Daniel J., Le, Thuy, Zhao, Wei, Lee, Leo, Mackenzie-Kludas, Charley, Mehdiabadi, Neda R., Halliday, Christopher, Gilham, Dean, Fu, Li, Nicholls, Stephen J., Johansson, Jan, Sweeney, Michael, Wong, Norman C.W., Kulikowski, Ewelina, Sokolowski, Kamil A., Tse, Brian W.C., Devilée, Lynn, Voges, Holly K., Reynolds, Liam T., Krumeich, Sophie, Mathieson, Ellen, Abu-Bonsrah, Dad, Karavendzas, Kathy, Griffen, Brendan, Titmarsh, Drew, Elliott, David A., McMahon, James, Suhrbier, Andreas, Subbarao, Kanta, Porrello, Enzo R., Smyth, Mark J., Engwerda, Christian R., MacDonald, Kelli P.A., Bald, Tobias, James, David E., Hudson, James E.

Source: In Cell 15 April 2021 184(8):2167-2182

Innate myeloid cells in the tumor microenvironment

Authors: Duhan, Vikas, Smyth, Mark J

Source: In Current Opinion in Immunology April 2021 69:18-28

Systemic administration of IL‐33 induces a population of circulating KLRG1hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma

Authors: Guillerey, Camille, Stannard, Kimberley, Chen, Jason, Krumeich, Sophie, Miles, Kim, Nakamura, Kyohei, Smith, Jessica, Yu, Yuan, Ng, Susanna, Harjunpää, Heidi, Teng, Michele WL, Engwerda, Christian, Belz, Gabrielle T, Smyth, Mark J

Source: Immunology and cell biology. 99(1):65-83

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100114307711.0x000001&indx=1&recIds=ETOCvdc_100114307711.0x000001

Cancer immunoediting and immune dysregulation in multiple myeloma

Authors: Nakamura, Kyohei ^*, Smyth, Mark J., Martinet, Ludovic ^**

Source: In Blood 10 December 2020 136(24):2731-2740

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells

Authors: Braun, Matthias, Aguilera, Amelia Roman, Sundarrajan, Ashmitha, Corvino, Dillon, Stannard, Kimberley, Krumeich, Sophie, Das, Indrajit, Lima, Luize G., Meza Guzman, Lizeth G., Li, Kunlun, Li, Rui, Salim, Nazhifah, Jorge, Maria Villancanas, Ham, Sunyoung, Kelly, Gabrielle, Vari, Frank, Lepletier, Ailin, Raghavendra, Ashwini, Pearson, Sally, Madore, Jason, Jacquelin, Sebastien, Effern, Maike, Quine, Brodie, Koufariotis, Lambros T., Casey, Mika, Nakamura, Kyohei, Seo, Eun Y., Hölzel, Michael, Geyer, Matthias, Kristiansen, Glen, Taheri, Touraj, Ahern, Elizabeth, Hughes, Brett G.M., Wilmott, James S., Long, Georgina V., Scolyer, Richard A., Batstone, Martin D., Landsberg, Jennifer, Dietrich, Dimo, Pop, Oltin T., Flatz, Lukas, Dougall, William C., Veillette, André, Nicholson, Sandra E., Möller, Andreas, Johnston, Robert J., Martinet, Ludovic, Smyth, Mark J., Bald, Tobias

Source: In Immunity 13 October 2020 53(4):805-823

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy

Authors: Weulersse, Marianne, Asrir, Assia, Pichler, Andrea C., Lemaitre, Lea, Braun, Matthias, Carrié, Nadège, Joubert, Marie-Véronique, Le Moine, Marie, Do Souto, Laura, Gaud, Guillaume, Das, Indrajit, Brauns, Elisa, Scarlata, Clara M., Morandi, Elena, Sundarrajan, Ashmitha, Cuisinier, Marine, Buisson, Laure, Maheo, Sabrina, Kassem, Sahar, Agesta, Arantxa, Pérès, Michaël, Verhoeyen, Els, Martinez, Alejandra, Mazieres, Julien, Dupré, Loïc, Gossye, Thomas, Pancaldi, Vera, Guillerey, Camille, Ayyoub, Maha, Dejean, Anne S., Saoudi, Abdelhadi, Goriely, Stanislas, Avet-Loiseau, Hervé, Bald, Tobias, Smyth, Mark J., Martinet, Ludovic

Source: In Immunity 13 October 2020 53(4):824-839

Tumor intrinsic and extrinsic immune functions of CD155

Authors: O’Donnell, Jake. S., Madore, Jason, Li, Xian-Yang, Smyth, Mark J. ^*

Source: In Seminars in Cancer Biology October 2020 65:189-196

Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma

Authors: Effern, Maike, Glodde, Nicole, Braun, Matthias, Liebing, Jana, Boll, Helena N., Yong, Michelle, Bawden, Emma, Hinze, Daniel, van den Boorn-Konijnenberg, Debby, Daoud, Mila, Aymans, Pia, Landsberg, Jennifer, Smyth, Mark J., Flatz, Lukas, Tüting, Thomas, Bald, Tobias, Gebhardt, Thomas, Hölzel, Michael

Source: In Immunity 15 September 2020 53(3):564-580

Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis

Authors: Kumar, Rajiv, Bunn, Patrick T., Singh, Siddharth Sankar, Ng, Susanna S., Montes de Oca, Marcela, De Labastida Rivera, Fabian, Chauhan, Shashi Bhushan, Singh, Neetu, Faleiro, Rebecca J., Edwards, Chelsea L., Frame, Teija C.M., Sheel, Meru, Austin, Rebecca J., Lane, Steven W., Bald, Tobias, Smyth, Mark J., Hill, Geoffrey.R., Best, Shannon E., Haque, Ashraful, Corvino, Dillon, Waddell, Nic, Koufariotis, Lambross, Mukhopadhay, Pamela, Rai, Madhukar, Chakravarty, Jaya, Singh, Om Prakash, Sacks, David, Nylen, Susanne, Uzonna, Jude, Sundar, Shyam, Engwerda, Christian R.

Source: In Cell Reports 25 February 2020 30(8):2512-2525

Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions

Authors: Stannard, Kimberley A., Lemoine, Sébastien, Waterhouse, Nigel J., Vari, Frank, Chatenoud, Lucienne, Gandhi, Maher K., Martinet, Ludovic, Smyth, Mark J., Guillerey, Camille

Source: In Blood Advances 11 June 2019 3(11):1681-1694

Tumor intrinsic and extrinsic immune functions of CD155

Authors: O'Donnell, Jake. S., Madore, Jason, Li, Xian-Yang, Smyth, Mark J.

Source: Seminars in cancer biology. 65:189-196

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100116678740.0x000001&indx=1&recIds=ETOCvdc_100116678740.0x000001

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

Authors: Fumagalli, Debora, Gelber, Richard D, Goulioti, Theodora, Hiltbrunner, Anita, Hui, Rita, Roschitzki, Heidi, Ruepp, Barbara, Boyle, Fran, Stahel, Rolf, Aebi, Stefan, Coates, Alan S, Goldhirsch, Aron, Karlsson, Per, Kössler, Ingrid, Fournarakou, Stamatina, Gasca, Adriana, Pfister, Rita, Ribeli-Hofmann, Sabrina, Weber, Magdelena, Celotto, Daniela, Comune, Carmen, Frapolli, Michela, Sánchez-Hohl, Magdalena, Huang, Hui, Mahoney, Caitlin, Price, Karen, Scott, Karolyn, Shaw, Holly, Fischer, Susan, Greco, Monica, King, Colleen, Andrighetto, Stefania, Piccart-Gebhart, Martine, Findlay, Heather, Jenkins, Michelle, Karantza, Vassiliki, Mejia, Jaime, Schneier, Patrick, Loi, Sherene ^*, Giobbie-Hurder, Anita, Gombos, Andrea, Bachelot, Thomas, Hui, Rina, Curigliano, Giuseppe, Campone, Mario, Biganzoli, Laura, Bonnefoi, Hervé, Jerusalem, Guy, Bartsch, Rupert, Rabaglio-Poretti, Manuela, Kammler, Roswitha, Maibach, Rudolf, Smyth, Mark J, Di Leo, Angelo, Colleoni, Marco, Viale, Giuseppe, Regan, Meredith M, André, Fabrice

Source: In The Lancet Oncology March 2019 20(3):371-382

Hide and seek: Plasticity of innate lymphoid cells in cancer

Authors: Bald, Tobias, Wagner, Marek, Gao, Yulong, Koyasu, Shigeo, Smyth, Mark J.

Source: In Seminars in Immunology February 2019 41

Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade

Authors: Minnie, Simone A., Kuns, Rachel D., Gartlan, Kate H., Zhang, Ping, Wilkinson, Andrew N., Samson, Luke, Guillerey, Camille, Engwerda, Christian, MacDonald, Kelli P.A., Smyth, Mark J., Markey, Kate A., Vuckovic, Slavica ^*, Hill, Geoffrey R.

Source: In Blood 18 October 2018 132(16):1675-1688

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment

Authors: Nakamura, Kyohei, Kassem, Sahar, Cleynen, Alice, Chrétien, Marie-Lorraine, Guillerey, Camille, Putz, Eva Maria, Bald, Tobias, Förster, Irmgard, Vuckovic, Slavica, Hill, Geoffrey R., Masters, Seth L., Chesi, Marta, Bergsagel, P. Leif, Avet-Loiseau, Hervé, Martinet, Ludovic, Smyth, Mark J.

Source: In Cancer Cell 9 April 2018 33(4):634-648

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy

Authors: Mastaglio, Sara ^*, Wong, Eric ^*, Perera, Travis, Ripley, Jane, Blombery, Piers, Smyth, Mark J., Koldej, Rachel, Ritchie, David

Source: In Blood Advances 27 February 2018 2(4):335-346

Adoptive Transfer of T Cells Modified with a Humanized Chimeric Receptor Gene Inhibits Growth of Lewis-Y-Expressing Tumors in Mice

Authors: Smyth, Mark J., Trapani, Joseph A., Scott, Andrew M.

Source: Proceedings of the National Academy of Sciences of the United States of America, 2005 Dec . 102(52), 19051-19056.

Access URL: https://www.jstor.org/stable/4152563

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

Authors: Loi, Sherene, Giobbie-Hurder, Anita, Gombos, Andrea, Bachelot, Thomas, Hui, Rina, Curigliano, Giuseppe, Campone, Mario, Biganzoli, Laura, Bonnefoi, Hervé, Jerusalem, Guy, Bartsch, Rupert, Rabaglio-Poretti, Manuela, Kammler, Roswitha, Maibach, Rudolf, Smyth, Mark J, Di Leo, Angelo, Colleoni, Marco, Viale, Giuseppe, Regan, Meredith M, André, Fabrice

Source: Lancet oncology. 20(3):371-382

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100111559278.0x000001&indx=1&recIds=ETOCvdc_100111559278.0x000001

Cancer immunoediting and resistance to T cell-based immunotherapy

Authors: O'Donnell, Jake S., Teng, Michele W. L., Smyth, Mark J.

Source: Nature reviews.Clinical oncology. 16(3):151-167

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100193247280.0x000001&indx=1&recIds=ETOCvdc_100193247280.0x000001

The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor‐infiltrating T cells

Authors: Lepletier, Ailin, Lutzky, Viviana P, Mittal, Deepak, Stannard, Kimberley, Watkins, Thomas S, Ratnatunga, Champa N, Smith, Corey, McGuire, Helen M, Kemp, Roslyn A, Mukhopadhyay, Pamela, Waddell, Nicola, Smyth, Mark J, Dougall, William C, Miles, John J

Source: Immunology and cell biology. 97(2):152-164

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100082757400.0x000001&indx=1&recIds=ETOCvdc_100082757400.0x000001